Global Information
회사소개 | 문의

전립선 비대증(BPH) : 주요 17개국 시장 예측(2016-2026년)

Epiomic Epidemiology Series: Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026

리서치사 Black Swan Analysis
발행일 2016년 03월 상품 코드 354594
페이지 정보 영문 48 Pages
가격
US $ 4,930 ₩ 5,659,600 PDF by E-mail (Single User License)
US $ 7,400 ₩ 8,495,200 PDF by E-mail (Site License)
US $ 8,900 ₩ 10,217,200 PDF by E-mail (Global License)


전립선 비대증(BPH) : 주요 17개국 시장 예측(2016-2026년) Epiomic Epidemiology Series: Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026
발행일 : 2016년 03월 페이지 정보 : 영문 48 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

전립선 비대증(BPH)은 배뇨를 힘들게 하는 비암성 전립선 비대입니다. 정확한 원인은 알려져 있지 않지만, 대부분의 경우 테스토스테론, 특히 안드로겐 디하이드로테스토스테론(androgen dihydrotestosterone)을 포함한 호르몬에 기인한 변화를 수반합니다.

주요 17개국 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 브라질, 일본, 인도, 터키, 스웨덴, 캐나다, 호주, 덴마크, 한국, 네덜란드, 중국)의 현재 전립선 비대증(BPH: Benign Prostatic Hypertrophy) 환자수(성별, 연령 그룹별)에 대해 조사 분석했으며, 현재 유병률, 질환 개요, 위험인자, 질환 진단과 예후, 주요 증상과 합병증 등의 정보를 전해드립니다.

1. 도표

2. 서론

3. 병인

4. 위험인자와 예방

5. 질환 진단

6. 변이 : 지역/민족별

7. 질환의 예후와 임상경과

8. 질환에 관련된 주요 합병증 및 특징

9. 환자수를 정량화하는 방법

10. 전립선 비대증 최대 환자수

11. 전립선 비대증(BPH) 환자의 특징

  • BPH에서 증상의 중증도와 빈도
  • BPH에서 요실금과 기능장애
  • 배뇨와 폐색
  • BPH 관련 동반질환

12. 약어

13. 관련 출판

14. 환자 기반 온라인 데이터베이스

15. 환자 기반 제품

16. 온라인 가격 데이터 및 플랫폼

17. 참고 문헌

18. 부록

LSH 16.03.28

영문목차

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Benign Prostatic Hypertrophy (BPH) Disease in 17 Major Markets

Benign Prostatic Hypertrophy (BPH) is a noncancerous (benign) enlargement of the prostate gland that can make urination difficult. The precise cause is not known but most likely involves changes caused by hormones, including testosterone and especially androgen dihydrotestosterone.

The prostate enlarges over time and is regarded as a normal aging process, with BPH being found to be common in males over the age of 60. However, if it is left untreated symptoms may worsen and the risks of urinary tract infections (UTIs) and acute urinary retention becomes higher and may require corrective surgery.

This report provides the current male prevalent population for BPH across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Sweden, Canada, Australia, Denmark, South Korea, Netherlands and China) split by 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of BPH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for BPH include:

  • Acute urinary retention (AUR)
  • Recurrent UTIs
  • Hydronephrosis
  • Renal failure
  • Prostate cancer

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global BPH's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of BPH and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on BPH's prevalent population.
  • Identify sub-populations within BPH which require treatment.
  • Gain an understanding of the specific markets that have the largest number of BPH patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions /Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Benign Prostatic Hypertrophy
  • Features of Clinically Diagnosed BPH Patients
    • Severity and Frequency of Symptoms in BPH
    • Urinary Incontinence and Retention in BPH
    • Bladder Emptying and Obstructions
    • Associated Co-morbid Conditions of BPH
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Figures

  • Prevalence of clinically relevant (symptomatic) BPH by age across the 17 major markets in 2016
  • Breakdown by country of clinically relevant BPH patients in 2016

List of Tables

  • IPSS questionnaire for suspected BPH patients
  • IPSS scoring and severity
  • Total prevalence of BPH, males (000s)
  • Prevalence of clinically relevant BPH, males (000s)
  • IPSS severity of clinically relevant BPH patients, males (000s)
  • Frequency of night-time urination in clinically relevant BPH patients, males (000s)
  • Frequency of urinary leakage in clinically relevant BPH patients, males (000s)
  • Urge incontinence in clinically relevant BPH patients, (000s)
  • AUR with moderate / severe symptoms in clinically relevant BPH patients, (000s)
  • Possible bladder outlet obstruction in clinically relevant BPH patients, males (000s)
  • Incomplete bladder emptying in clinically relevant BPH patients, males (000s)
  • Erectile dysfunction in clinically relevant BPH patients, males (000s)
  • Prostate cancer in clinically relevant BPH patients, males (000s)
  • Abbreviations and acronyms used in the report
  • USA Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • France Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Germany Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Italy Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Spain Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Brazil Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Japan Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • India Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Turkey Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Sweden Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Canada Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Australia Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Denmark Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • South Korea Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of BPH disease by 5-yr age cohort, males (000s)
  • China Prevalence of BPH disease by 5-yr age cohort, males (000s)
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research